epithelialization; however, this was an incidental finding, and he did not have any systemic signs or symptoms of any rheumatologic conditions or history of HLA-B27related uveitis. Cryopreserved AMT has been described for the following therapeutic indications: persistent epithelial defect and deep corneal ulcer. 7,8 Other indications include Stevens-Johnson syndrome, recurrent pterygium, recurrent Mooren's ulcer, viral keratitis, and sterile corneal melt. 9,10 To date, there has not been a reported case for AMT after corneal melt secondary to collagen crosslinking and TCAT. The use of AMT avoided an emergent corneal transplant surgery for the patient. CONCLUSIONS Corneal melt is a rare and significant complication that can occur after C3R-TCAT. Careful patient selection and counselling are important. The underlying etiology in this case is likely multifactorial. Recognizing and optimizing potential risk factors such as lagophthalmos and blepharitis before surgery will potentially prevent this complication.